NCT06570031 - ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 9, 2021

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Hormone Receptor-positive Breast CancerHER2-negative Breast CancerMetastatic Breast CancerRecurrent Breast Cancer

Interventions

DRUG

ONO-4578

Specified dose on specified days

DRUG

letrozole

Specified dose on specified days

DRUG

Palbociclib

Specified dose on specified days

DRUG

abemaciclib

Specified dose on specified days

Trial Locations (13)

Aichi Cancer Center Hospital, Nagoya

Nagoya University Hospital, Nagoya

Chiba Cancer Center, Chiba

National Cancer Center Hospital East, Kashiwa-shi

St. Marianna University Hospital, Kawasaki-shi

Kanagawa Cancer Center, Yokohama

University Hospital Kyoto Prefectural University of Medicine, Kyoto

Tohoku University Hospital, Sendai

Osaka International Cancer Institute, Osaka

Saitama Cancer Center, Shinden

National Cancer Center Hospital, Chuo-ku

The Cancer Institute Hospital Of JFCR, Koto-ku

Tokyo Medical University Hospital, Shinjuku-ku